Filtros de búsqueda

Lista de obras de

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

3D microvascular model recapitulates the diffuse large B-cell lymphoma tumor microenvironment in vitro.

artículo científico publicado en 2017

8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma ⬇️

artículo científico publicado el 15 de septiembre de 2010

90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease

artículo científico publicado en 2014

A CAR against CAR for unintended consequences

scientific article published on 01 February 2020

A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma

scientific article published on 09 December 2020

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

artículo científico publicado en 2004

A novel proteoliposomal vaccine elicits potent antitumor immunity in mice

artículo científico publicado en 2007

A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma

artículo científico publicado en 2007

A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones

artículo científico publicado en 2007

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy

article

A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis

scientific article published on 01 August 2019

ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.

artículo científico publicado en 2011

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

artículo científico publicado en 2018

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

artículo científico publicado en 2016

Absence of Grail promotes CD8+ T cell anti-tumour activity

artículo científico

Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma

artículo científico publicado en 2011

Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy

artículo científico publicado en 2020

Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma

artículo científico publicado en 2019

Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion

artículo científico publicado en 2004

An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non-Hodgkin lymphoma

Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets

artículo científico publicado en 2014

Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy

scientific article published on 01 September 2020

Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma

scientific article published on 06 February 2020

Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study

artículo científico publicado en 2020

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

artículo científico publicado en 2017

BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma

artículo científico publicado en 2007

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma

artículo científico publicado en 2020

Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells

artículo científico publicado en 2016

CAR T-Cell Therapy in Large B-Cell Lymphoma

scientific article published on 01 March 2018

CAR Treg cells: prime suspects in therapeutic resistance

artículo científico publicado en 2022

CAR-T efficacy: is conditioning the key?

scientific article published on 01 April 2019

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

artículo científico publicado en 2015

CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity

scientific article published on 25 April 2019

CXCR5+CD8+ T cells are localized in B cell follicles and germinal centers and exhibit regulatory and anti-tumor function.

artículo científico publicado en 2015

Cancer immunotherapy: Strategies for personalization and combinatorial approaches

artículo científico publicado en 2015

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma

artículo científico publicado en 2015

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

artículo científico publicado en 2020

Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo

artículo científico publicado en 2004

Chimeric Antigen Receptor T Cells in Hematologic Malignancies

artículo científico publicado en 2017

Chimeric Antigen Receptor T-cell Therapy Toxicities

artículo científico publicado en 2020

Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma

artículo científico publicado en 2019

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

article by Michael M Boyiadzis et al published 4 December 2018 in Journal for Immunotherapy of Cancer

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

artículo científico publicado en 2017

Clinical Features of Rituximab-associated Gastrointestinal Toxicities

scientific article published on 01 June 2019

Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.

artículo científico publicado en 2017

Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

artículo científico publicado en 2020

Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma

artículo científico publicado en 2020

Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera

artículo científico publicado en 2006

Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma

artículo científico publicado en 2013

Copy number alterations detected as clonal hematopoiesis of indeterminate potential

scientific article published on 19 June 2017

Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment

artículo científico publicado en 2013

De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era

artículo científico publicado en 2019

Detection of circulating tumour DNA in patients with aggressive B‐cell non‐Hodgkin lymphoma ⬇️

artículo científico publicado el 25 de junio de 2013

Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach

artículo científico publicado en 2015

Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine ⬇️

artículo científico publicado el 1 de octubre de 2001

Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials

scientific article published on 13 April 2008

Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review

scientific article published on 07 November 2019

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions.

artículo científico publicado en 2017

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

scientific article published on 12 April 2022

Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma

artículo científico publicado en 2016

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

artículo científico publicado en 2014

EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.

artículo científico publicado en 2010

Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes

scientific article published on 26 February 2019

Editorial: CAR T-Cell Therapies in Hematologic Tumors

artículo científico publicado en 2020

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients

scientific article published on 02 April 2020

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

artículo científico publicado en 2008

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma

artículo científico publicado en 2017

Essential role of TAK1 in regulating mantle cell lymphoma survival.

artículo científico publicado en 2012

Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.

artículo científico publicado en 2009

FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.

artículo científico publicado en 2014

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era

artículo científico publicado en 2016

Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma

scientific article published on 01 May 2019

Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions

artículo científico publicado en 2011

Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma

scientific article published on 06 March 2019

Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy

artículo científico publicado en 2019

Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines ⬇️

artículo científico publicado el 23 de noviembre de 2010

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL

scientific article published on 01 March 2020

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

artículo científico publicado en 2011

Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment

artículo científico publicado en 2016

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma

scientific article published on 30 July 2020

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study

artículo científico publicado en 2017

Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy

artículo científico publicado en 2018

Hodgkin lymphoma untreated for six years presenting with tracheoesophageal fistula

artículo científico publicado en 2012

Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen

artículo científico publicado en 2004

IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay

artículo científico publicado en 2016

Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement

artículo científico publicado en 2020

Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma

artículo científico publicado en 2016

Identification of human idiotype-specific T cells in lymphoma and myeloma

artículo científico publicado en 2011

Idiotype Vaccination As Consolidation Therapy: Time for Integration Into Standard of Care for Follicular Lymphoma? ⬇️

artículo científico publicado el 31 de octubre de 2011

Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.

artículo científico publicado en 2002

Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission

scientific article published on 20 February 2020

Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells ⬇️

artículo científico publicado el 18 de marzo de 2013

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis.

artículo científico publicado en 2018

Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma

artículo científico publicado en 2020

Induction of TLR4-dependent CD8+ T cell immunity by murine β-defensin2 fusion protein vaccines

artículo científico publicado en 2011

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma

artículo científico publicado en 2014

Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.

artículo científico publicado en 2016

Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma

artículo científico publicado en 2020

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

artículo científico publicado en 2012

Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial

scientific article published on 28 March 2019

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.

artículo científico publicado en 2015

Leptomeningeal carcinomatosis in metastatic prostate cancer

artículo científico publicado en 2002

Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma

scientific article published on 15 September 2020

Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.

artículo científico publicado en 2017

Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

scientific article published on 02 September 2018

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma

scientific article published on 28 February 2019

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

artículo científico publicado en 2018

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

artículo científico publicado en 2019

Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.

artículo científico publicado en 2016

Managing the toxicities of CAR T-cell therapy

artículo científico publicado en 2019

Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.

artículo científico publicado en 2016

MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response

artículo científico publicado en 2011

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

artículo científico publicado en 2011

Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma

artículo científico publicado en 2015

Mutations and microenvironment collude in FL

artículo científico publicado en 2015

Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients ⬇️

artículo científico publicado el 9 de julio de 2012

Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

artículo científico publicado en 2012

Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen

artículo científico publicado en 2013

Not So FASt: Tumor Cells Resisting Death Drive CAR T-cell Dysfunction

scientific article published on 01 April 2020

Novel BAFF-receptor antibody to natively folded recombinant protein eliminates drug resistant human B-cell malignancies in vivo

artículo científico publicado en 2017

Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system

artículo científico

Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma

artículo científico publicado en 2013

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

artículo científico publicado en 2013

Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

scientific article published on 12 February 2019

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

artículo científico

Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel

artículo científico publicado en 2020

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

artículo científico publicado en 2020

Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?

scientific article published on 07 February 2020

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.

artículo científico publicado en 2016

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial

artículo científico publicado en 2014

Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.

artículo científico publicado en 2015

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

artículo científico publicado en 2017

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

artículo científico publicado en 2008

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

artículo científico publicado en 2012

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

artículo científico publicado en 2018

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

artículo científico publicado en 2012

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes

artículo científico publicado en 2012

Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol

artículo científico publicado en 2018

Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma

artículo científico publicado en 2013

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

artículo científico publicado en 2015

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

artículo científico publicado en 2015

Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma

artículo científico publicado en 2009

Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma

artículo científico publicado en 2007

Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report

artículo científico publicado en 2005

Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.

artículo científico publicado en 2017

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma

artículo científico publicado en 2009

Platelet activating factor-induced expression of p21 is correlated with histone acetylation

artículo científico publicado en 2017

Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL

artículo científico publicado en 2018

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

artículo científico publicado en 2019

Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy

artículo científico publicado en 2018

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

artículo científico

Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity

artículo científico publicado en 2015

Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

artículo científico publicado en 2020

Primary mediastinal large B-cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy

artículo científico publicado en 2020

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.

artículo científico publicado en 2016

Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles

artículo científico publicado en 2006

Prospective isolation of clonogenic mantle cell lymphoma-initiating cells

artículo científico publicado en 2010

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

artículo científico publicado en 2013

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma

artículo científico publicado en 2009

Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma.

artículo científico publicado en 2018

Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function

scientific article published on 02 August 2019

Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma.

artículo científico publicado en 2017

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

artículo científico publicado en 2020

Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare

scholarly article by Sang T Kim et al published 14 May 2019 in Journal for Immunotherapy of Cancer

Reply

scientific article published on 23 March 2019

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy

artículo científico publicado en 2018

Role of the tumor microenvironment in mature B-cell lymphoid malignancies

artículo científico publicado en 2016

Rush hour traffic: directing T cells to tumor

artículo científico publicado en 2014

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

artículo científico publicado en 2020

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

artículo científico publicado en 2013

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

artículo científico publicado en 2014

Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection

artículo científico publicado en 2019

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

artículo científico publicado en 2016

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

artículo científico publicado en 2020

Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma

artículo científico publicado en 2014

Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography

artículo científico publicado en 2015

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

artículo científico publicado en 2020

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

scientific article published on 01 December 2020

Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement

artículo científico publicado en 2018

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

scientific article published on 08 January 2019

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

scientific article published on 13 May 2020

Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models

artículo científico publicado en 2007

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas

artículo científico publicado en 2012

Targetable genetic alterations of () drive immunoglobulin expression in diffuse large B cell lymphoma

artículo científico publicado en 2019

Targeting B cell malignancies through human B cell receptor specific CD4 T cells

artículo científico publicado en 2015

Targeting B-cell malignancies through human B-cell receptor specific CD4+ T cells

artículo científico publicado en 2016

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

artículo científico publicado en 2022

Targeting Wnt pathway in mantle cell lymphoma-initiating cells.

artículo científico publicado en 2015

Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes

artículo científico

Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma

artículo científico

Targeting the tumor niche to treat cancer

artículo científico publicado en 2015

The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities

artículo científico publicado en 2020

The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma

artículo científico publicado en 2020

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

artículo científico publicado en 2014

The promise of CAR T-cell therapy in aggressive B-cell lymphoma

artículo científico publicado en 2018

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma

artículo científico publicado en 2018

The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.

artículo científico publicado en 2016

Therapeutic lymphoma vaccines: importance of T-cell immunity

artículo científico publicado en 2006

Therapeutic vaccine for lymphoma

artículo científico publicado en 2007

Therapy of newly diagnosed follicular lymphoma ⬇️

artículo científico publicado el 11 de diciembre de 2012

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.

artículo científico publicado en 2018

Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma

artículo científico publicado en 2012

Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development

artículo científico publicado en 2014

Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma

artículo científico publicado en 2005

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

artículo científico publicado en 2020

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

artículo científico publicado en 2017

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

scientific article published on 21 February 2018

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

artículo científico publicado en 2019

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma

artículo científico publicado en 2020

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

artículo científico publicado en 2020

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

scientific article published on 22 August 2019

Vaccination strategies in follicular lymphoma

artículo científico publicado en 2009

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma

artículo científico publicado en 2011

Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity

artículo científico publicado en 2009

Vaccine therapy for B-cell lymphomas: next-generation strategies

artículo científico publicado en 2007

Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma

artículo científico publicado en 2005

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda